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Abstract
Background: The effect of Human Immunodeficiency Virus-1 (HIV-1) on CD4+ Th2 cells is hypothesized to affect
parasitological diagnosis of Schistosoma mansoni using Kato Katz technique. Thus, the use of more sensitive technique
such as Point-of-Care Circulating Cathodic Antigen (POC-CCA) test is recommended. However, the sensitivity of this
diagnostic test in diagnosing S.mansoni infection and the usefulness of it in monitoring efficacy of praziquantel drug in
presence of HIV-1 co-infection remains inconclusive. The Primary objective of the present study was to assess accuracy
of the POC-CCA test in diagnosing S.mansoni infection before and after praziquantel treatment in adult population
co-infected with HIV -1.
Methods: A prospective longitudinal study was conducted among individuals aged 15–55 years at Igalagala village,
north-western Tanzania. At baseline and 4 weeks after treatment, a single stool and urine samples were collected from
each participants. Kato Katz (KK) technique and Point-of-Care Circulating Cathodic Antigen tests were used for
diagnosis of Schistosoma mansoni.
Results: At baseline, based on KK and POC-CCA, the prevalence of S.mansoni was 57.8% (95%CI: 52.9–62.4) and 87.5%
(95%CI: 83.9–90.4). Based on KK technique and POC-CCA test, 3.6% and 5.7% of the study participants were co-infected
with S.mansoni and HIV-1. At baseline, in the general population, the sensitivities of POC-CCA test using KK technique
and combine gold standard were 96.3%(95%CI: 93.1–98.3) and 97.6%(95%CI:95.5–98.9) respectively. In the HIV-1
seropositive group, at baseline, the sensitivities of POC-CCA test using KK technique and combined gold standards, were
93.3%(95%CI:68.1–99.8) and 96%(95CI%:79.6–99.9). Four weeks after treatment, in general population, the sensitivities of
POC-CCA test using KK technique and combined gold standards were 47.8%(95%CI:26.8–69.4) and 84.4%(95%CI:74.4–91.
7). In the HIV-1 seropositive group, using KK technique, the sensitivity was 100% (95%CI:2.5–100).
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Conclusion: The sensitivity of POC-CCA in diagnosing S.mansoni infection was higher than KK technique in adult
individuals likely to have low infection intensity and co-infected with HIV-1. However, its sensitivity decreases following
praziquantel treatment but remained higher than Kato Katz technique. If the goal of the post-treatment is to identify
uncured individuals, then POC-CCA test offers the best choice.
Keywords: Schistosoma mansoni, HIV-1, Point-of-care circulating Cathodic antigen, Sensitivity, Specificity, Adult, Tanzania
Background
In the past three decades, epidemiological studies have dem-
onstrated an overlap of Human Immunodeficiency (HIV-1)
and Schistosoma mansoni infections in Sub-Saharan Africa
[1, 2], leading to co-infection in proportion of individuals liv-
ing in highly endemic regions [3, 4]. It is hypothesized that
helminths infections such as Schistosoma mansoni may ex-
acerbate HIV-1 transmission or progression to AIDS in Af-
rica [2, 3]. This is based on observations that infection with
these parasites cause a chronic stimulation of the immune
system with a strong bias towards a type 2 CD4+helper T
cell (Th2) response [3, 5]. This in turn affects the ability of
the host’s immune system to control HIV-1 replication [3].
Conversely, HIV-induced destruction of CD4+ T cells,
especially those that secrete type 2 cytokines [6, 7];
this may affect granuloma formation and alter egg ex-
cretion efficiency.
Studies in suppressed animal models has demonstrated
that the excretion of S.mansoni eggs is immune
dependent, and that T-cells, specifically anti-eggs Th2 re-
sponse [8] are necessary for the transposition and excre-
tion of eggs from the host blood stream into the
intestinal lumen [7]. HIV-1 infection has been demon-
strated to affect S.mansoni eggs excretion efficiencies
[9]. This observation have been described to impact on
diagnosis of S.mansoni infection using Kato Katz tech-
nique, which depend on examination of the parasite eggs
[9]. This may lead to underestimation of the prevalence
and intensity of infection before and after praziquantel
treatment in adult population co-infected or not with
HIV-1 [9]. The potential for HIV-1 to affect S. mansoni
eggs excretion makes the detection of circulating schis-
tosome antigens released insitu particularly important in
detecting S. mansoni infection [10]. In this context, a
Point-of-Care Circulating Cathodic Antigen test has
been developed as an alternative test to the Kato Katz
technique. This test has been extensively assessed in
sub-Saharan Africa [10, 11]. However, the results on the
sensitivity of circulating antigen detection tests in adult
individuals co-infected or not with HIV-1 evaluated be-
fore and after praziquantel treatment have yielded con-
trasting results [12, 13]. The discrepancies observed
between these studies calls for further studies to further
evaluate the sensitivity of POC-CCA test in the adult
population and assess its effectiveness in evaluating mass
drug administration treatment programs in adult popula-
tion. In this context, the primary objective of this study
was to assess the sensitivity and specificity of Point-of-Care
Circulating Cathodic Antigens (POC-CCA) test in diag-
nosing S. mansoni infection in comparison to parasito-
logical Kato Katz technique (regarded as “gold standard”)
and a combined gold standard (infection-positive by either
Kato Katz technique or POC-CCA-positivity (assuming
100% specificity of the POC-CCA test) [14] among adult
population living in a fishing village of north-western
Tanzania, either co-infected or not with HIV-1. Secondar-
ily, the study assessed the usefulness of Point-of-Care Cir-
culating Cathodic Antigen test in monitoring the efficacy
(CCA clearance at 4 weeks following treatment) of prazi-
quantel drug in presence of HIV-1 infection among adult
population.
Methods
Study area
The study area is described in details in [15, 16], briefly,
the present study was conducted at Ilemela district,
Mwanza region, located at 32-34°E and 2-40S, on the
southern shores of the Lake Victoria, north-western
Tanzania. Specifically, the study was conducted at Igala-
gala village located at shoreline of the Lake Victoria. The
choice of this village was based on its close proximity to
the lake, high prevalence and intensity of S. mansoni in-
fection [16] and high HIV-1 prevalence [15]. The major-
ity of the populations are of Sukuma tribe and other are
migrating tribes such as Wakerewe, Wajita and Wakara.
The main economic activities are fishing and farming.
The Lake is the major source of water and mainly used
for bathing, cooking, drinking and recreation. Because of
high water contact, the residents have high risk of being
infected with S.mansoni and carry highest infection in-
tensity [15]. Annual mass drug administration (MDA)
using praziquantel against S. mansoni infection mainly
focus to schoolchildren and adult population is not
included.
Study design, inclusion and exclusion criteria
This was a prospective longitudinal study, which was
conducted in October–November 2016, was character-
ized with two cross-sectional surveys at baseline and
4 weeks after praziquantel treatment (Fig. 1). All adult
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individuals aged 15–55 years of age and lived in the
study village for > 2 years were eligible for recruitment
into the study. The length of stay in the risky areas for
transmission of S.mansoni has been demonstrated to in-
crease the chances for acquiring the infection and devel-
oping the related hepatosplenic morbidities [17]. The
study excluded individuals who were on antiretroviral
treatment (ART) due to the fact that excretion of S.man-
soni eggs is a function of immune status as measured in
term of CD4+ Th2 cells [9] and taking antiretroviral ther-
apy have effects on the level of CD4+ Th2 cells [4]. Thus,
including individuals who were on antiretroviral therapy
would confound the results of Kato Katz technique
among the HIV-1 infected group. The study also ex-
cluded individuals with CD4+ < 350cells/μL from the
prospective survey. By the time this study was con-
ducted, the country guideline for ART initiation required
that all individuals diagnosed with HIV-1 infection and
having CD4+ < 350cells/μL to be initiated treatment.
Therefore, it was considered unethical to included
HIV-1 infected individuals with CD4+ < 350cells/in a
prospective study. Lastly, individuals with history of tak-
ing anti-schistosomiasis in the past 6-month were also
excluded to remove the confounding effects of the treat-
ment on the sensitivity of the diagnostic test especially
parasitological technique.
Fig. 1 Study profile
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Sample size and sampling procedures
For calculation of the sample size, we used the formula
for comparing two independent proportional to estimate
sample size for comparing sensitivity/specificity of the
POC-CCA test and that of the Kato Katz technique (re-
ferred as a Gold standard) [18]. At 95% confidence inter-
val and a power of 80% to detect a difference of 10%
from sensitivity of 85% (i.e. P1 = 85%, P2 = 75% and P0 =
77.5%) [18], the required sample size was 472 partici-
pants but only 419 participants were enrolled into the
study. Although the sample size was below the estimated
sample size, our power to detect the estimated difference
remained > 90%.
Selection of the study participants has been describe
in details in [15], briefly a random sampling procedure
was used to select households and household members
to participate in the study. Prior to study implementa-
tion, a list of households and household members was
obtained to allow random sampling of eligible individ-
uals from randomly selected households.
Data collections
Questionnaires
A pre-tested questionnaire was used to collect demo-
graphic information of the study participants, past history
of HIV testing, use of anti-schistosomiasis treatment and
use of anti-retroviral therapy.
Examination of Schistosoma mansoni circulating cathodic
(CCA) antigen and Schistosoma haematobium eggs
For screening of S.mansoni infection, a point-of-care
Circulating-Cathodic-Antigen (CCA) (Rapid Medical
Diagnostic- http://www.rapid-diagnostics.com/, Batch
number: 33827) which uses urine sample was employed.
A single urine sample was collected from each partici-
pating individuals [19] and the POC-CCA test was used
to screen for the antigen. The POC-CCA test detects the
presence of schistosome CCA released from worms ex-
creted in the host’s urine [19]. The test was performed
as per manufacturer instructions (Rapid Medical Diag-
nostic- http://www.rapid-diagnostics.com/) and “trace”
results were considered as positive. Qualified laboratory
technician were blinded for the Kato Katz parasitological
results and HIV-1 sero-status of the study participants
used the test to screen for S.mansoni infection.
For screening of S.haematobium infection, the same
urine sample collected for POC-CCA screening was
used. Urine sample was grossly examined for the pres-
ence of gross heamaturia and using Hemastix® for pres-
ence of micro-haematuria [20]. Then, the urine sample
was filtered (pore aperture 20 μm; Sefar AG, Heiden,
Switzerland), filter placed on a slide and examined under
a microscope for presence of S. haematobium eggs [20].
Examination of human immunodeficiency Virus-1
Human Immunodeficiency Virus-1 (HIV-1) testing was
done according to Tanzanian National HIV algorithm
[21]. This involved the use of Determine® and UNGold
qualitative tests [21]. Before, HIV testing, participants
received counseling from qualified HIV counselors.
Then, finger prick blood sample was collected from each
consenting study participants and screening for HIV-1
infection using both test. Results were recorded based
on the manufacturer instructions. The quantification of
CD4+ cells was done using a FACS Calibur machine
(Becton and Dickinson, BD Biosciences, San Jose, CA,
USA), following standard manufacturer procedures.
Parasitological examination of Schistosoma mansoni eggs
in stool samples
For diagnosis of S. mansoni infection, a single stool sam-
ple was collected from each study participant at baseline
and 4 weeks after praziquantel treatment. On the
screening day, each participating individual was provided
with a container for stool sample collection. Stool sam-
ples were collected fresh, labeled with a specific study
number and processed using Kato Katz thick smear
technique using a template of 41.7 mg per thick smear
[22]. From each collected stool sample, four Kato Katz
thick smears were prepared. Three-laboratory technician
supervised by a senior laboratory technician examined
all Kato Katz thick smears at the National Institute
for Medical Research, Mwanza, Tanzania. For quality
assurance purposes, 10% of all positive and negative
slides were re-examined by an independent laboratory
technician.
Data analysis
A Microsoft Excel system was used for double data entry
and data analysis was performed using Stata Version 15
(StataCorp, 2017, Stata statistical software: release 13.
College Station, TX: StataCorp LP, Taxes, USA). Num-
bers and percentages summarized categorical variables.
Comparison of proportions/categorical variables was
done using chi-square (χ2)/fisher exact where appropri-
ate. For continuous variables descriptive statistics were
reported as means with standard deviation for normally
distributed variable and medians with interquartile
ranges (IQR) for variables that were not normally dis-
tributed. The arithmetic mean of S. mansoni egg counts
for each participant was calculated from the counts of
four Kato Katz thick smears and multiplied by 24 to ob-
tain individual eggs per gram of faeces. Schistosoma
mansoni egg counts were logarithmically transformed to
check for normality but only non-transformed means
are presented. Mean egg counts for S. mansoni between
sex and age were compared using Student-t-test (two
groups) or ANOVA (more than two groups). Intensity of
Mazigo et al. Archives of Public Health  (2018) 76:29 Page 4 of 11
infection was categorized according to WHO criteria as:
1–99 epg, 100–399 epg, ≥400epg defined as low, moder-
ate and heavy intensities of infection respectively [23].
The sensitivity, specificity, positive and negative predict-
ive values of the POC-CCA test was calculated using two
gold standards, (1) egg-positive by Kato Katz technique
(as reference standard for diagnosis of S. mansoni infec-
tion) and (2) combined gold standard (infection-positive
by either Kato Katz technique or POC-CCA-positivity
(assuming 100% specificity of the POC-CCA test) [14].
Specificity, i.e. the percentage of negative individuals cor-
rectly identified as such, was calculated as described in
[24]. Similarly, sensitivity was calculated as percentage of
positive individuals correctly identified as such [24]. In
addition, positive predictive value (PPV = proportion of
positive test results that are truly positive) and negative
predictive value (NPV = proportion of negative test results
that are truly negative) were calculated after calculating
sensitivity and specificity of the diagnostic tests [24]. Stat-
istical significance was assigned at P < 0.05 for all analyses.
Ethical consideration and confidentiality
Ethical approval was sought from the joint Ethical and
Review Committee of Bugando Medical Centre and
Catholic University of Health and Allied Sciences. The
study received further permission from the district ad-
ministrative and division authorities. Kiswahili translated
informed consent forms were used to obtain participants
consent to participate in the study and assent for those
who were aged 15- < 18 years. Written informed consent
was obtained from guardians/parents of all participants
aged 15- < 18 years. For illiterate participants, a thumb-
print was used to sign the consent/assent forms after a
clear description of the study objectives was given to
them. To maintain confidentiality, all the demographic
and other clinical data of the study participants were
kept in a closed cabinet and whenever the data were
accessed no participants name were disclosed, only iden-
tification number of the participants were used to iden-
tify participants. All study participants infected with S.
mansoni were treated with praziquantel (40 mg/kg) ac-
cording to WHO guidelines [25].
Results
Demographic characteristics of study participants
A total of 419 study participants were enrolled in this
study, of these 46.1% (n = 193/419) and 53.9% (n = 226/
419) were female and male respectively. The median age
of the study participants was 30 years (IQR: 22–42 years).
Table 1 shows the age and sex distribution of the study
participants from Igalagala village. All of the study par-
ticipants were from Igalagala village located along the
shoreline of the Lake Victoria. All of the study partici-
pants performed their economic activities within the
village. The main economic activities of the study partic-
ipants were farming, fishing and fish processing and
small-scale business.
Prevalence of HIV-1 infection and determination of CD4+
levels
The overall prevalence of HIV-1 was 6.9% (n = 29/419,
95%CI: 4.8–9.8). The median CD4+ cell counts was
329cells/μL (Interquartile range: 299–526).
Pre-treatment baseline prevalence and intensity of
Schistosoma mansoni infection based on Kato Katz
technique
Based on Kato Katz technique, the overall prevalence of
Schistosoma mansoni infection was 57.8% (n = 242/419,
95%CI: 52.9–62.4), with female study participants having
the highest prevalence than male participants (67.4%
versus 49.6%, χ2 = 13.5186, P < 0.001). There was a rela-
tionship between age and S.mansoni infection, the youn-
gest age group (14–20 years) had the highest prevalence
compared to the oldest age group (51–55 years) which
had lower prevalence compared to the youngest age
groups (75.9% versus 36.8%, χ2 = 21.9706, P < 0.001). The
overall arithmetic mean of egg intensity was 64.78 ±
161.08 (95%CI: 49.3–80.3). Female participants had
higher arithmetic mean egg intensity compared to male
participants (101.8 ± 209.6, 95%CI: 71.9–131.5 versus
33.21 ± 92.5, 95%CI: 21.1–45.3, F = 19.69, P < 0.001). Ma-
jority of the study participants had low infection inten-
sity (70.7%), moderate (23.6%) and heavy infection
intensity (5.8%). In general, more female participants
than male participants had moderate to heavy infection
intensity (χ2 = 12.9664, P < 0.002).
Pre-treatment prevalence of Schistosoma mansoni
infection based on point-of-care circulating Cathodic
antigen tests
Based on the Point-of-Care Circulating Cathodic Anti-
gen test, the overall prevalence of S.mansoni among
adult participants was 87.4% (365/419, 95%CI: 83.5–
90.0). Female individuals had the highest prevalence
compare to male participants (91.2%, n = 176/193 versus
83.6%, n = 189/226, χ2 = 5.3043, P < 0.02). In relation to
age, the youngest age group (15–20 years) had the high-
est prevalence of infection (χ2 = 10.6675, P < 0.03).
Table 1 Demographic characteristics (age and sex distribution)
of the study participants
Sex Age groups (in years)
15–20
years
21–30
years
31–40
years
41–50
years
51–55
years
Female 39 (46.9%) 63 (44.4%) 34 (41.9%) 26 (46.4%) 31 (54.4%)
Male 44 (53%) 79 (56.6%) 47 (58%) 30 (53.6%) 26 (45.6%)
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Pre-treatment prevalence of Schistosoma mansoni
infection based on point-of-care circulating Cathodic
antigen tests and Kato Katz technique
Overall, a total of 233/365 (63.78%) study participants
were detected to have S. mansoni infection by both Kato
Katz technique and POC-CCA test. The POC-CCA test
detected 96.3% (233/242) of all the study participants
who had detectable S. mansoni eggs in their stool based
on Kato Katz technique. The POC-CCA test detected an
additional of 132 study participants infected with S.
mansoni who were missed by Kato Katz technique.
Co-infection of Schistosoma mansoni and HIV-1 infection
Based on Kato Katz technique, 6.2% (15/242) of the
study participants were co-infected with HIV-1 and S.
mansoni infection. Based on POC-CCA test, 6.6% (24/
365) of the study participants were co-infected with
HIV-1 and S.mansoni infection. Overall, 48.3% (14/29)
of the HIV-1 seropositive participants were both KK/
CCA positive for S.mansoni infection (meaning that
48.3% of study participants were HIV-1 positive and
were identified by both KK and CCA to be infected with
S.mansoni).
Prevalence and intensity of Schistosoma mansoni 4 weeks
after treatment based on Kato Katz technique and point-
of-care circulating Cathodic antigen test
At 4 weeks follow-up after praziquantel treatment, a
total of 202 study participants who were infected by S.
mansoni based on either POC-CCA test or Kato Katz
technique were available for re-examination. Of these
participants, 111 participants were infected by S.mansoni
based on POC-CCA test and Kato Katz technique at
baseline, at 4 weeks after PZQ treatment, 70.3% (78/111)
had no infection and only 29.7% (33/111) remained with
S.mansoni infection based on both Kato Katz technique
and POC-CCA test (Fig. 1). For those who were identi-
fied to be infected by S.mansoni using POC-CCA test
only at baseline, 85 were available for re-examination at
4 weeks after PZQ treatment, of these, 29.4%(25/85)
remained POC-CCA positive for S.mansoni and 70.6%
(60/85) had no S.mansoni infection. At baseline, only 9/
242 (3.7%) of the study participants were identified by
Kato Katz technique (had POC-CCA negative results) to
be infected by S.mansoni. At 4 weeks after treatment, six
(6) of them were available for re-examination, 4/6
(66.7%) had no infection and only 2/6(33.3%) remained
with detectable eggs in their stool samples (Fig. 1).
In relation to HIV-1 serostatus, of the 15 HIV-1 sero-
positive who were co-infected with S.mansoni infection
based on Kato Katz technique, eight (8) of them were
available for re-examination, 25% (2/8) remained with
S.mansoni eggs in their stool samples at 4 weeks after
treatment (Fig. 1). Based on POC-CCA test, of the 24
HIV-1 seropositive who had POC-CCA positive test at
baseline, 12 were available for re-examination, of these
33.3% (4/12) remained with CCA positive results at
4 weeks of follow-up (Fig. 1). There was no difference
in age and sex differences between those who were
present and those who were absent at 4 weeks of
follow-up (χ2 = 5.7496, P = 0.23). In addition, there was a
mean difference in infection intensity between those
who were present and those who were absent at 4 weeks
of follow-up (t = 2.3329, P < 0.02), with those who were
absent had a higher infection intensity.
Diagnostic characteristics of the point-of-care circulating
cathodic antigen test before treatment
Table 2 shows pre-treatment sensitivity and specificity of
POC-CCA test using Kato Katz technique as a “gold
standard”. At baseline, the sensitivity and specificity of
POC-CCA test were 96.3% (95%CI: 93.1–98.3) and 25.4%
(95%CI:19.2–32.5) for the general population. The nega-
tive and positive predictive values for the general popula-
tion are shown in Table 2. The sensitivity and specificity
of the POC-CCA test using the combined gold standard
(infection-positivity by either egg-or-POC-CCA positivity,
assuming 100% specificity of the POC-CCA test) are
shown in Table 2. The overall sensitivity slightly improved
from 96.3%(95%CI: 93.1–98.3) to 97.6% (95%CI: 95.5–
98.9) for the general population.
In relation to HIV-1 serostatus, the results obtained
using Kato Katz technique as a gold standard and
combined gold standard are shown in Table 2. Using
the Kato Katz technique as a gold standard, the sensi-
tivity of POC-CCA test was 93.3% (95%CI: 68.1–98.8)
and specificity was 28.6% (95%CI: 8.4–58.1), Table 2.
Then, Using the combined gold standard (infection-
positivity by either egg-or-POC-CCA positivity, as-
suming 100% specificity of the POC-CCA test), the
sensitivity of the POC-CCA test improved to 96.0%
(95%CI: 79.6–99.9).
Diagnostic characteristics of the point-of-care circulating
cathodic antigen test after treatment
The results obtained using Kato Katz technique as a
gold standard and combined gold standard (infec-
tion-positivity by either egg-or-POC-CCA positivity,
assuming 100% specificity of the POC-CCA test)
4 weeks after treatment are shown in Table 2. After
4 weeks of treatment, using Kato Katz technique as a
gold standard, the overall the sensitivity and specifi-
city of POC-CCA test were 47.8% (95%CI: 26.8–69.4)
and 74.7% (95%CI: 67.9–80.8) respectively. Using the
combined gold standard, at 4 weeks after treatment,
the overall sensitivity of the POC-CCA test was 84.4%
(95%CI: 74.4–91.7) (Table 2).
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Diagnostic characteristics of the Kato Katz technique
compared to combined gold standard pre-and-post
treatment
At pre-treatment, the sensitivity of the Kato Katz tech-
nique compared to combined gold standard was
64.7%(95%CI: 59.6–69.5), Table 3. Four weeks after treat-
ment, a very low sensitivity of Kato Katz technique was
recorded at 35.6% (95%CI: 24.7–47.7).
Discussion
The main findings from this study indicate that,
pre-and-post treatment sensitivity and specificity of the
point-of-care circulating Cathodic Antigen test using
combine gold standard were higher than that of Kato
Katz technique, both in the general population and the
HIV-1 seropositive group. We observed declined in sen-
sitivity of POC-CCA test 4 weeks after treatment, when
Table 3 Diagnostic characteristics of the Kato Katz technique using a combined gold standard in the general population and HIV-1
seropositive group before and 4 weeks after treatment
Diagnostic test Sensitivity Specificity Positive predictive value Negative predictive value
General population
Pre-treatment combined gold standarda
Kato Katz 64.7% (95%CI:59.6–69.5) 100% (95%CI:92.1–100) 100% (95%CI:98.5–100) 25.4% (19.2–32.5)
Post-treatment combined gold standarda
Kato Katz 35.6% (95%CI:24.7–47.7) 100% (95%CI:97.4–100) 100 (95%CI:86.8–100) 74.7% (95%CI:67.9–80.8)
In the HIV-1 seropositive group
Pre-treatment combined gold standarda
Kato Katz 60% (95%CI:38.7–78.9) 100% (95%CI:39.8–100) 100% (95%CI:78.2–100) 28.6% (95%CI:8.4–58.1)
Post-treatment combined gold standarda
Kato Katz 33.3% (95%CI:43–77.7) 100% (95%CI:59–100) 100% (95%CI:15.8–100) 63.6% (95%CI:30.8–89.1)
aInfection-positive by either egg-or-POC-CCA-positivity (assuming 100% specificity of the Kato Katz result)
Table 2 Diagnostic characteristics of the Point-of-care Circulating Cathodic Antigen test using Kato Katz technique as gold standard
and combined gold standard in the general population and HIV-1 seropositive group before and 4 weeks after treatment
Diagnostic test Sensitivity Specificity Positive Predictive Value Negative Predictive Value
Pre-treatment
General population
(i) Using Kato Katz technique as gold standard
POC-CCA 96.3% (95%CI:93.1–98.3) 25.4% (95%CI: 19.2–32.5) 63.8% (95%CI: 58.7–68.8) 83.3% (95%CI: 70.7–92.1)
(ii) Using combined gold standarda
POC-CCA 97.6% (95%CI:95.5–98.9) 100 (95%CI:92.1–100) 100 (95%CI:99–100) 83.3% (95%CI:70.7–92.1)
In the HIV-1 seropositive group
(i) Using Kato Katz technique as a gold standard
POC-CCA 93.3% (95%CI:68.1–99.8) 28.6% (95%CI:8.4–58.1) 58.8% (95%CI:36.6–77.9) 80% (95%CI:28.4–99.5)
(ii) Using combined gold standarda
POC-CCA 96% (95%CI:79.6–99.9) 100% (95%CI:39.8–100) 100% (95%CI:85.8–100) 80% (95%CI:28.4–99.5)
Four weeks after praziquantel treatment
In general population
(i) Using Kato Katz technique as gold standard
POC-CCA 47.8% (95%CI: 26.8–69.4) 74.7% (95%CI: 67.9–80.8) 19% (95%CI: 9.9–31.4) 92.1% (95%CI: 86.5–95.8)
(ii) Using combined gold standarda
POC-CCA 84.4% (95%CI:74.4–91.7) 100% (95%CI:97.4–100) 100% (95%CI:94.5–100) 92.1% (95%CI:86.5–95.8)
In the HIV-1 seropositive group
(i) Using Kato Katz technique as gold standard
POC-CCA 100% (95%CI:2.5–100) 63.6% (95%CI:30.8–89.1) 20% (95%CI:0.5–71.6) 100% (95%CI:59–100)
POC-CCA-Point-of-Care Circulating Cathodic Antigen
aInfection-positive by either egg-or-POC-CCA-positivity (assuming 100% specificity of the POC-CCA result)
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KK technique was used as a gold standard, but this
changed to a higher sensitivity when a combined gold
standard was used. We observed high praziquantel cure
rates both in HIV-1 seropositive and seronegative groups
infected with S.mansoni evaluated at 4 weeks after
treatment.
At pre-treatment assessment, our data indicated that
POC-CCA test achieved a sensitivity of 96.3% but had
low specificity in detecting S.mansoni infection using
Kato Katz technique as a gold standard in the general
population. Similar findings were noted by previous
similar studies conducted elsewhere in African setting
using Kato Katz technique as a gold standard [26, 27].
Conversely, at pre-treatment, the POC-CCA test
achieved high sensitivity (93.3%) but low specificity in
detecting S.mansoni infection in the HIV-1 seropositive
group. A high pre-treatment intensity of S.mansoni in-
fection appears to influence the high sensitivity of
POC-CCA test [28]. Significant positive correlations be-
tween positivity of POC-CCA test and S. mansoni eggs
counts have been noted in previous study in Brazil and
Kenya [28, 29]. This partly could explain a high
pre-treatment sensitivity of the POC-CCA test in the
two groups, which is reported to decrease in individuals
with light infections (< 100 eggs/g of feaces) [26, 28].
The low POC-CCA test specificities in part are ex-
plained by the low sensitivities of the Kato Katz tech-
nique [26]. Our pre-treatment findings on the sensitivity
and specificity of POC-CCA test are comparable to pre-
vious findings published among primary school children
in endemic areas of Uganda (94.8%) [26] but higher than
86.9% and 56.3% observed in Cote d’Ivoire [27]. The
variation in prevalence and intensity of S.mansoni infec-
tion between geographical settings seems to influence
the sensitivity of the POC-CCA test. In region with low
prevalence such as in Cote d’Ivoire, the sensitivity of
POC-CCA test was lower (56.3%) despite that three
POC-CCAs were performed to increase sensitivity [27].
In our present study, 32.5% and 35% of the study partici-
pants identified by POC-CCA test having S.mansoni in-
fection in the general population and in the HIV-1
seropositive group were missed by Kato Katz technique.
This observation indicate that, if selective treatment is
done based on the KK test, these individuals would be
erroneously indicated not infected. Previous studies have
demonstrated reduce efficiency of S.mansoni eggs excre-
tion in HIV-1 individuals co-infected with S.mansoni in-
fection [1, 9, 15, 30]. Thus, the use of a more sensitive
diagnostic test/technique than Kato Katz technique is
justifiable in adult population likely to be co-infected
with HIV-1 and S.mansoni and likely to have light to
moderate intensity of infection [26].
At 4 weeks post-treatment using Kato Katz technique
as a gold standard, the sensitivity of POC-CCA test
decreased to below 50% but its specificity improved to
almost to 75% in the general population. A similar find-
ings have been reported in Uganda, in which at 1 and
4 weeks post-praziquantel treatment, the sensitivity of
the POC-CCA test decreased from 91.7% to 66.7% and
73% [26]. A plausible explanation for this observation is
the increase in POC-CCA false positives due to increase
in specificity [26, 29, 31]. Alternatively, the decline in in-
tensity of infection at post-praziquantel treatment affects
the performance of POC-CCA tests [28]. A noted
pre-treatment correlation between S.mansoni egg loads
and the strength of positivity of POC-CCA test has been
reported [26, 29, 32]. An interesting questions which
needs follow-up is the relationship between parasites
antigen levels at pre-and-post praziquantel treatment
and reduced eggs intensity following praziquantel treat-
ment. The fact that Circulating Cathodic Antigen are re-
leased by mature adult worms which are also
responsible for producing eggs [19], it will be interesting
to understanding this relationship.
In the HIV-1 seropositive group, the POC-CCA test
attained a sensitivity of 100% using Kato Katz technique
as a gold standard. Is worthwhile mentioning that at
4 weeks post-treatment evaluation, our analysis suffered
from low number of HIV-1/S.mansoni co-infected indi-
viduals to give a meaningful statistical analysis on the
sensitivity and specificity of the POC-CCA test. This is a
limitation for this study. Evidence from our data indicate
that for the HIV-1/S.mansoni co-infected individuals
who returned after 4 weeks for re-examination, at least
60% were Kato-Katz negative/POC-CCA positive. Simi-
lar findings have been reported in rural Zimbabwe,
where a low CCA clearance rates was observed in
HIV-1/S.mansoni co-infected individuals [30]. In term of
public health, this findings adds weight on the need to
included highly sensitive diagnostic test especially when
screening and evaluating MDA programs which involve
adult individuals in areas which are co-endemic to
HIV-1/S.mansoni infection.
Understanding the limitations of Kato Katz technique
as gold standard diagnostic test [33], we developed an
assumption that the POC-CCA test is 100% specific and
constructed an artificial gold standard based on either
Kato Katz technique egg positive or POC-CCA test sero-
positivity [14]. Using the combined gold standard re-
sulted in improved in the sensitivity of POC-CCA test
compared to what was observed when using Kato Katz
technique as a gold standard, both at pre-treatment
(96.3% versus 97.6%) and 4 weeks after treatment (47.8%
versus 84.4%) in the general population. Conversely, for
the HIV-1 seropositive group, the use of combined gold
standard resulted in increased in sensitivity of
POC-CCA test compared to what was recorded when
using Kato Katz technique before treatment (93.3%
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versus 96%). However, using a combined gold standard,
the sensitivity of Kato Katz technique before and 4 weeks
after treatment, both in the general population and in
the HIV-1 seropositive group remained lower than that
of POC-CCA test. These findings indicates the needs to
supplement Kato Katz technique in either epidemio-
logical surveys or when assessing the efficacy of prazi-
quantel drug especially in adult individuals likely to have
light infection intensity or co-infected with HIV-1/
S.mansoni. The use of more than one diagnostic tests to
screen parasitic diseases is highly recommended in order
to improve the sensitivity of field based diagnostic tech-
niques. This increases the chances of detecting individ-
uals with different levels of infection intensity in
endemic areas and allows precise measure of the burden
of disease when planning for community based interven-
tion measures [34, 35].
Efficacy of praziquantel drugs as measured by parasito-
logical cure rates between the HIV-1 seropositive groups
co-infected with S.mansoni and HIV-1 seronegative
group infected only with S.mansoni parasite did not vary
significantly. Similar findings were reported in north-
western Tanzania, in which parasitological cure rates of
62.6% and 48.3% were reported among HIV-1 seronega-
tive group infected with S.mansoni and HIV-1-S.mansoni
co-infected group [36]. At 12 weeks assessment of prazi-
quantel treatment, Kallestrup et al., [13] in Zimbabwe re-
corded parasitological cure rates of 86% and 85% in HIV-1
seropositive group co-infected with S.mansoni and those
only infected with S.mansoni [13]. However, at 4 weeks of
praziquantel treatment evaluation, Karanja et al., in [12]
recorded lower cure rates of 53% and 59% among HIV-1
seronegative group infected with S.mansoni and those
who were co-infected with HIV-1 and S.mansoni [22].
The variation in pre-treatment intensity of S.mansoni, in-
tensity of transmission and low sensitivity to praziquantel
in some of the strains of S.mansoni parasite can partly ex-
plains the observed differences in cure rates between the
HIV-1 seronegative groups and groups co-infected with
HIV-1 and S.mansoni [37].
The observation of Kato Katz-negative/POC-CCA posi-
tive results at 4 weeks post-praziquantel treatment may
reflects existing of adult or juvenile stages not affected by
treatment and newly acquired infection in high transmis-
sion setting, like that of the present study area. In general,
the presence of Kato Katz negative/POC-CCA positive re-
flects continued infection in treated individuals (having
worms which continue to release CCA). With majority of
Kato Katz negative individuals remaining harboring light
intensity of infections as shown by POC-CCA test in the
present study and those of other authors [26, 29], these
findings clearly suggest the need for repeated rounds of
treatment for persistent infection per year contrasting the
current recommendation of once per year [23]. This
means more costs to the MDA programs. To reduce
costs, the currently used Kato Katz technique to evaluate
MDA program need to be supplemented with a more sen-
sitive assay such as POC-CCA test.
The present study was not conducted without limita-
tion, the low number of HIV-1/S.mansoni co-infected
individuals affected our analysis on the evaluation of
sensitivity and specificity of POC-CCA test and Kato
Katz technique at 4 weeks after treatment. Moreover,
the use of a single stool sample to examine for S.man-
soni infection owing the day to day variability of S.man-
soni eggs output may have affected the performance of
the Kato Katz technique.
Conclusion
Our findings indicate that the POC-CCA test had higher
sensitivity at pre-and-post praziquantel treatment than Kato
Katz technique using a combined gold standard. The sensi-
tivity of POC-CCA test remained higher than Kato-Katz
technique even in the presence of HIV-1 co-infection be-
fore and after praziquantel treatment. However, the
POC-CCA test had low specificity at pre-treatment which
increased at 4 weeks post-praziquantel treatment. Although
POC-CCA test have shown promising results for its use in
post-treatment evaluation of MDA program, further studies
are needed to elucidate the full potential of the test in
evaluating the impact of MDA programs in population liv-
ing in areas with different transmission intensity.
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